Seres Therapeutics, Inc. MCRB
3.52
(0.10)
(2.76%)
as of 25 Sep
- Market cap
- $36.0M
- P/E
- 0.0×
Follow MCRB
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 22.21 | 29.69 |
+8 more quarters Free account |
P/S ratio |
40.67 | 55.89 | 89.49 | 1.32 | |
P/FCF ratio |
0.00 | 0.00 | 122.63 | 0.00 | |
P/Operating CF |
(3.42) | (5.20) | (8.96) | 76.39 | |
P/B ratio |
2.22 | 3.21 | 2.98 | 3.86 | |
Price to Tangible BV |
2.22 | 3.21 | 2.98 | 3.86 | |
EV/Sales |
86.82 | 103.66 | 128.00 | 1.75 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(3.19) | (3.74) | 168.80 | (9.69) | |
EV/FCF |
(3.19) | (3.74) | 175.40 | (9.56) | |
Quick Ratio |
2.04 | 1.55 | 2.40 | 2.16 | |
Current Ratio |
2.11 | 1.65 | 2.56 | 2.30 | |
Net Debt/EBITDA |
0.76 | 1.48 | 2.48 | 2.22 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.02 | 0.01 | 0.01 | 0.79 | |
Operating CF/Net income |
(4.89) | 0.82 | 0.96 | 0.27 | |
Capex/Depreciation |
0.02 | 0.00 | 0.19 | (0.01) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
1,241.98% | 3,685.75% | 2,667.58% | 3,594.30% | |
Selling, General and Administrative Expense of Revenue |
959.38% | 2,254.19% | 1,721.23% | 2,699.72% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
236.28% | 493.30% | 730.37% | 707.12% | |
Graham Net Nets |
(0.32) | (0.70) | (0.34) | (0.29) | |
Graham Number |
0.00 | 0.00 | 8.67 | 8.53 | |
Earnings Yield |
(30.80%) | (58.29%) | 4.50% | 3.37% | |
Free Cash Flow Yield |
(66.93%) | (49.64%) | 0.82% | (13.87%) | |
Revenue per Share |
0.08 | 0.04 | 0.05 | 0.04 | |
Operating CF per Share |
(2.31) | (1.71) | (1.66) | 0.25 | |
Capex per Share |
0.00 | 0.00 | 0.02 | 0.00 | |
Free Cash Flow per Share |
(2.31) | (1.71) | (1.64) | 0.25 | |
Cash per Share |
1.61 | 3.11 | 5.17 | 5.44 | |
Shareholders Equity per Share |
3.56 | 2.77 | 4.99 | 4.99 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.56 | 2.77 | 4.99 | 4.99 | |
Free Cash Flow |
(22.38) | (16.36) | (14.53) | 2.20 | |
Working Capital |
22.32 | 12.49 | 30.05 | 29.10 | |
Capital Expenditures |
0.01 | — | 0.18 | (0.01) | |
Net Current Asset Value |
(24.71) | (59.28) | (44.60) | (48.25) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
(0.02) | 0.00 | (0.41) | 0.02 | |
Net Profit Margin |
622.42% | (5,562.29%) | (3,501.14%) | 2,337.32% | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
13.08 | 1.50 | 1.29 | 9.69 | |
Average Payables |
1.69 | 2.25 | 2.88 | 4.97 | |
Average Assets |
122.69 | 140.90 | 139.00 | 161.11 | |
Average Common Equity |
33.74 | 38.48 | 29.00 | 33.81 |
Columns are period end dates